Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1626971 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $13.19Day +1.15%Mkt cap $1.1B1Y +201.1%Off 52W high −51.1%Vol (1Y) 180.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,601 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest21.5% of sh out |
| Days to cover12.6d |
| 13F net flow (QoQ)+10.66% |
| Top-10 13F concentration52.0% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$44.2M |
| ROE−32.6% |
| ROIC−84.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+71.3% |
| 1Y+201.1% |
| 3Y+486.2% |
| 5Y+531.1% |
| 10Y−0.8% |
| Since incept. (ann.)−0.7% |
Total return through 2026-07-30 · series begins 2016-03-23. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)180.3% |
| Ann. volatility (3Y)125.7% |
| Sharpe (1Y)1.11 |
| Sharpe (3Y)0.92 |
| Max drawdown (1Y)−56.4% |
| Max drawdown (3Y)−70.5% |
| Beta (3Y vs SPY)2.57 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 7.2M | $105M | 8.53% | +0.0% |
| BlackRock, Inc. | 6.2M | $90M | 7.33% | +21.8% |
| STATE STREET CORP | 3.6M | $52M | 4.25% | +27.9% |
| ADAMS STREET PARTNERS LLC | 3.3M | $48M | 3.90% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2M | $47M | 3.85% | new |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.9M | $43M | 3.47% | +8453.9% |
| Vivo Capital, LLC | 2.8M | $41M | 3.34% | +25.6% |
| MORGAN STANLEY | 2.5M | $37M | 2.98% | −30.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.15 | — | — | — |
| 2025-09-30 | 2025-11-04 | −$0.12 | — | — | — |
| 2025-06-30 | 2025-08-07 | −$0.10 | — | — | — |
| 2025-03-31 | 2025-05-08 | −$0.13 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
